Rheumatology Network's Top 5: October 15, 2021
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending October 15, 2021.
E Michael Lewiecki, MD: Controversies in Osteoporosis
E Michael Lewiecki, MD, discusses his CCR West presentations entitled, “Controversies in Osteoporosis” and “What's New in Osteoporosis for 2021?”
Click the image to view the story.
Higher Disease Control Linked to Better Outcomes for Patients With Psoriatic Arthritis
The post hoc analyses evaluated health-related quality of life and efficacy across 4 subgroups treated with either ixekizumab or adalimumab.
Click the image to view the story.
Hydroxychloroquine did not Protect Patients With Rheumatic Disease Against COVID-19
Investigators analyzed the potential beneficial effect of hydroxychloroquine to prevent COVID-19 infection in patients with rheumatic disease.
Click the image to view the story.
The Financial Impact of Juvenile Idiopathic Arthritis
“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.
Click the image to view the story.
High Rates of Retinopathy Seen in Patients With Systemic Lupus Erythematosus
Approximately a third of systemic lupus erythematosus patients experience ocular involvement, which may be linked to disease pathophysiology.
Click the image to view the story.
